Navigation Links
Genomic Health to Present at BIO CEO & Investor Conference
Date:2/8/2008

REDWOOD CITY, Calif., Feb. 8 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Kim Popovits, Genomic Health's President and Chief Operations Officer, will present at the BIO CEO & Investor Conference in New York, NY on Feb. 12, 2008 at 10:15 a.m. Eastern Time.

To access the live and subsequently archived webcast of the presentation, visit the Investor Relations section of Genomic Health's website at http://investor.genomichealth.com. Please connect to the website at least 15 minutes prior to the beginning of the presentation to allow for any necessary software downloads. An archived replay will be available for three months after the live presentation.

About Genomic Health

Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test, Oncotype DX(R), which has been shown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in a large portion of early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com.


'/>"/>
SOURCE Genomic Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Transgenomic, Inc. Reports Second Quarter 2007 Results
2. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
3. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
4. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
5. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
6. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
7. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
8. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
9. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
10. BioNanoatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
11. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Pa. , Sept. 17, 2014 BioClinica®, ... and eClinical Solutions, today announced three of its experts ... for Clinical Data Management to be held September ... Nevada . The Company also announced the innovative ... raise overall quality in clinical trials acquired earlier this ...
(Date:9/17/2014)... PA & Rockville, MD (PRWEB) September 17, 2014 ... won a Small Business Innovation Research (SBIR) grant to ... immunotherapy. The award will provide ITI with approximately $255,000 ... Tree nuts, a leading cause of food allergy, affect ... cause of anaphylaxis behind peanut allergy. Tree nut exposure ...
(Date:9/17/2014)... MA (PRWEB) September 17, 2014 Terracon ... version of its TerraPure tank . This addition ... is molded from FDA-compliant linear polyethylene and available in ... pre-installed fittings and ships in two weeks or less. ... features and benefits found in Terracon’s existing TerraPure tank ...
(Date:9/17/2014)... , Sept. 17, 2014 Intarcia ... quantitative data from a study of the cost and ... the 50 th Annual Meeting of the European ... poster session today, Christian Frois , Ph.D., of ... a series of planned Intarcia-sponsored, retrospective studies to characterize ...
Breaking Biology Technology:BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3Terracon Introduces Pre-Engineered TerraPure® Tank for Ultrapure Water Applications 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5
... (OTC Bulletin Board: WDSTD ), a development ... an initial $3.25 million funding in conjunction with its ... controlled by Lonza Walkersville ("Lonza Agreement").  Lonza Walkersville is ... of the world,s leading suppliers to the pharmaceutical, healthcare ...
... FutureFuel Corp. (OTC Bulletin Board: FTFL ) filed ... special cash dividend of $0.20 per share. The ... a special cash dividend of U.S. $0.20 per share on ... 2010. The dividend is payable September 30, 2010. ...
... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; ... in data.results) { first_result = data.results[r]; break; } for (var key in first_result) { //s += key ...
Cached Biology Technology:Regenicin Completes Acquisition of Worldwide Exclusive Know-How Technology License from Lonza Walkersville 2Shire plc - Statement re ProAmatine 2Shire plc - Statement re ProAmatine 3Shire plc - Statement re ProAmatine 4Shire plc - Statement re ProAmatine 5Shire plc - Statement re ProAmatine 6
(Date:9/17/2014)... decline, grasses have returned to some once-denuded patches of ... those places seems healthy again, but a new study ... coastal protection remains diminished. , "We,ve got ... back," said ecologist Mark Bertness, professor of biology at ... journal Biological Conservation . "The metric of a ...
(Date:9/17/2014)... faster since the 1960s. The typical development phases of ... accelerated -- by as much as 70 percent. This ... scientists from Technische Universitt Mnchen based on long-term data ... since 1870. Their findings were published recently in ... was a hot topic, with the very survival of ...
(Date:9/17/2014)... new crime unit designed to fight food fraud ... meat being passed off as beef scientists from ... They describe their approach, which represents a vast improvement ... and Food Chemistry . , Hans-Ulrich Humpf and colleagues ... problem. But they also say that adding, for example, ...
Breaking Biology News(10 mins):Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3
... lab-made version of a human protein alleviates symptoms of ... be the basis for a new arthritis drug for ... and Infectious Disease (NIAID), part of the National Institutes ... a cell surface receptor, thus blocking transmission of chemical ...
... research with the flatworm, planaria, offers new clues ... The Forsyth Institute have discovered how the worm's ... Forsyth scientists have found that gap-junction (microscopic ... this signaling. This research, led by Dr. Michael ...
... production of a protein called vasostatin may prove a promising ... of print in Gut. , Pancreatic cancer is the fifth ... is extremely difficult to treat. Only 3% of affected patients ... that has remained static for the past three decades. , ...
Cached Biology News:Synthetic Protein Eases Arthritis Symptoms in Mice 2New understanding of regeneration gained by Forsyth scientists 2Jefferson researchers find nanoparticle shows promise in reducing radiation side effects 2
MW5...
Mouse GM CSF Construction Kit provides antigen affinity purified polyclonal capture and tracer antibodies, and antigen standard for development of approximately ten microplate assays....
... GeneBLAzer cell-based assays utilize the membrane-permeant ... the negatively charged fluorescent beta-lactamase substrates, ... readily enter the cell, where cleavage ... them into their negatively charged forms, ...
Inquire...
Biology Products: